Amitriptyline overdose treatment by pegylated anionic liposomes

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Pharmacology

Background:

• Amitriptyline overdose presents a significant clinical challenge.
• Current treatments for amitriptyline toxicity have limitations.
• Liposomes offer a potential platform for drug sequestration and detoxification.

Purpose of the Study:

• To investigate the efficacy of anionic liposomes with varying lipid compositions and polyethylene glycol (PEG) modifications in sequestering amitriptyline from human serum.
• To determine the optimal liposome formulation for maximizing amitriptyline binding and minimizing protein interactions.
• To assess the stability and drug-binding capacity of liposomes upon storage.

Main Methods:

• Liposomes were formulated using different lipids, including DOPG, DMPC, DPPE-mPEG-2000, and CH.
• Liposome size, PEG inclusion (5% optimal), and lipid composition (95:5 DOPG:DPPE-mPEG-2000) were systematically varied.
• Amitriptyline sequestration was measured in buffer and human serum across a concentration range of 1-20 μM.
• Protein interaction shielding and storage stability (1 month) were evaluated.

Main Results:

• Liposome size did not significantly affect drug uptake.
• Optimal PEG incorporation was found at 5%, with 95:5 DOPG:DPPE-mPEG-2000 liposomes showing high efficacy.
• Absolute amitriptyline reduction of 99% was achieved in both buffer and serum.
• Nearly 90% reduction in free drug concentration relative to serum binding without liposomes was observed.
• Liposomes maintained drug binding ability after one month of storage.

Conclusions:

• Anionic liposomes incorporating PEG demonstrate significant potential for rapidly reducing toxic serum amitriptyline concentrations.
• The optimized liposome formulation effectively sequesters amitriptyline while minimizing protein interactions.
• These liposomes represent a promising therapeutic strategy for managing amitriptyline overdose, with potential for long-term storage.